Leukemia-Related Signaling Pathways Among HTLV-1-Derived Adult T Cell Leukemia/Lymphoma and Asymptomatic Carriers in Comparison to Normal Group.
Saber SoltaniSayed-Hamidreza MozhganiRoozbeh RoohinezhadSetareh Hedayati EmamiMah Hedayati EmamiSetayesh SolookiMina Fattah HesariNiloofar DoroozehMehdi NorouziPublished in: AIDS research and human retroviruses (2024)
Human T cell lymphotropic virus type 1 (HTLV-1) is associated with adult T cell leukemia/lymphoma (ATLL), a fetal malignant infection. Recently, HTLV-1 new asymptomatic carriers (ACs) have frequently been reported among blood donors. Reaching the profound concept of HTLV-1-associated molecular pathogenesis could result in finding novel therapeutic strategies. The current study aimed to determine leukemia-related signaling regulation in ATLL. Thirty participants were evaluated in 3 groups, including 10 ATLL patients, 10 ACs, and 10 normal controls. Blood samples were isolated without any chemotherapy history from ATLL patients. Also, blood samples were recovered from ACs and normal individuals. White blood cells isolation was done on the collected blood samples. After this, RNA was extracted from the prepared samples and used for the cDNA synthesis. TAX and HTLV-1 basic leucine zipper factor as viral genes and cellular genes, including MKP-1 , EVI-1 , JNK-1 , FOXO-1 , AKT-1 , DEPTOR , MTOR , and JUN , were investigated using real-time PCR. The mean age of ATLL patients was 53.2 ± 7.32 years, and 9 (90%) were male. The EVI-1 and FOXO-1 expression levels were significantly associated with ATLL patients compared with the internal control. However, the significant differences in expression of other genes in the remaining groups were not seen. Discovering viral and cellular signaling pathways that regulate HTLV-1 transformation is essential. A novel therapeutic strategy for ATLL-regulating cellular signaling pathways in vivo could be considered. Therefore, clinical trials using activators and inhibitors of related cellular signaling pathways for cell therapy of ATLL are recommended. It is recommended that more investigation be conducted on FOXO-1 and EVI-1 to target these genes and reveal the molecular pathogenesis of ATLL.
Keyphrases
- signaling pathway
- end stage renal disease
- ejection fraction
- newly diagnosed
- cell therapy
- pi k akt
- genome wide
- clinical trial
- acute myeloid leukemia
- induced apoptosis
- poor prognosis
- cell proliferation
- stem cells
- peritoneal dialysis
- prognostic factors
- acute coronary syndrome
- endothelial cells
- gene expression
- young adults
- cell death
- epithelial mesenchymal transition
- long non coding rna
- radiation therapy
- oxidative stress
- patient reported outcomes
- autism spectrum disorder
- binding protein
- endoplasmic reticulum stress
- placebo controlled
- nucleic acid
- clinical evaluation
- locally advanced